Pathologic assessment of tumor-associated macrophages and their histologic localization in invasive breast carcinoma

Journal of the Egyptian National Cancer Institute

Table 2 Relation between CD68 expression in both tumor nest and stroma and clinicopathologic characteristics

Variable	Total	CD68 in tumor nest			CD68 in tumor stroma
Variable	Total	Low N = 31 N (%)	High N = 29 N (%)	p	Low N = 30 N (%)	High N = 30 N (%)	p
Age (years) mean ± SD		52.81 ± 11.88	49.52 ± 11.34	0.278	52.17 ± 12.19	50.27 ± 11.19	0.532
Size
< 5 cm	39	23 (59)	16 (41)	0.123	25 (64.1)	14 (35.9)	0.003*
≥ 5 cm	21	8 (38.1)	13 (61.9)	0.123	5 (23.8)	16 (76.2)	0.003*
Grade
GII	32	18 (56.3)	14 (43.8)	0.448	18 (56.3)	14 (43.8)	0.301
GIII	28	13 (46.4)	15 (53.6)	0.448	12 (42.9)	16 (57.1)	0.301
Nodal metastasis
Negative	26	17 (65.4)	9 (34.6)	0.063	17 (65.4)	9 (34.6)	0.037*
Positive	34	14 (41.2)	20 (58.8)	0.063	13 (38.2)	21 (61.8)	0.037*
Staging
I	3	2 (66.7)	1 (33.3)	0.118	3 (100)	0 (0)	0.153
II	32	20 (62.5)	12 (37.5)		17 (53.1)	15 (46.9)
III	25	9 (36)	16 (64)		10 (40)	15 (60)
Vascular invasion
Negative	22	9 (40.9)	13 (59.1)	0.205	15 (68.2)	7 (31.8)	0.032*
Positive	38	22 (57.9)	16 (42.1)	0.205	15 (39.5)	23 (60.5)	0.032*
ER
Negative	13	6 (46.2)	7 (53.8)	0.653	7 (53.8)	6 (46.2)	0.754
Positive	47	25 (53.2)	22 (46.8)	0.653	23 (48.9)	24 (51.1)	0.754
PR
Negative	26	14 (53.8)	12 (46.2)	0.768	14 (53.8)	12 (46.2)	0.602
Positive	34	17 (50)	17 (50)	0.768	16 (47.1)	18 (52.9)	0.602
Her2
Negative	45	22 (48.9)	23 (51.1)	0.456	23 (51.1)	22 (48.9)	0.766
Positive	15	9 (60)	6 (40)	0.456	7 (46.7)	8 (53.3)	0.766
Ki-67
≤ 14%	29	16 (55.2)	13 (44.8)	0.599	15 (51.7)	14 (48.3)	0.796
> 14%	31	15 (48.4)	16 (51.6)	0.599	15 (48.4)	16 (51.6)	0.796
Molecular subtypes
Luminal A	27	15 (55.6)	12 (44.4)	0.535	14 (51.9)	13 (48.1)	0.475
Luminal B	24	13 (54.2)	11 (45.8)		10 (41.7)	14 (58.3)
Triple negative	9	3 (33.3)	6 (66.7)		6 (66.7)	3 (33.3)